MedTrace Logo

MRD Detection by NGS in Pediatric B-ALL

NCT05973032 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 430

Last updated 2024-01-24

No results posted yet for this study

Summary

This retrospective analysis aims to investigate pediatric patients with B-cell acute lymphoblastic leukemia who were detected for minimal residual disease (MRD) using next-generation sequencing (NGS). The study will utilize second-generation sequencing technology to analyze the rearrangement of the immunoglobulin heavy chain (IGH), immunoglobulin kappa light chain (IGK), and immunoglobulin lambda light chain (IGL) genes in these patients. Patients will be stratified based on NGS-MRD levels, and the relationship between NGS-MRD and Event-Free Survival (EFS) will be evaluated.

Conditions

  • Acute Lymphoblastic Leukemia, Pediatric

Interventions

OTHER

MRD

Calculate the 3-year EFS based on the MRD status (MRD positive and negative groups)

Sponsors & Collaborators

  • The Children's Hospital of Zhejiang University School of Medicine

    lead OTHER

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05973032 on ClinicalTrials.gov